Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on several parameters of Epstein-Barr virus infection

Distinctive properties of DNA polymerases induced by herpes simplex virus type-1 and Epstein-Barr virus

The properties of DNA polymerases induced by two human herpesviruses, herpes simplex virus type-1 (HSV-1) and Epstein-Barr virus (EBV), have been compared. The HSV-1 and EBV polymerases can be distinguished from one another by differences in the elution profiles in phosphocellulose and single-stranded DNA cellulose columns. Although both enzymes require monovalent cations for optimum activity, the HSV-1 enzyme requires ammonium sulfate whereas the EBV enzyme activity is inhibited by it; on the other hand, the EBV polymerase requires KCl. Other reaction requirements are also different for the two viral enzymes. Thus, when the EBV DNA polymerase was assayed under conditions optimum for the HSV-1 DNA polymerase, only 15% of its activity was expressed. Differences were also noted in sensitivities of the two viral enzymes to the 5'-triphosphates of nucleoside analogs with antiherpesvirus activity such as BVdU, IVdU, ACV, FIAC and IdUrd. The HSV-1 polymerase was more sensitive than the EBV DNA polymerase to inhibition by phosphonoacetate, phosphonoformate, aphidicolin and N-ethylmaleimide. However, the EBV DNA polymerase was more sensitive than HSV-1 DNA polymerase to heat treatment at 42 degrees C. Thus, the marked differences between the two viral enzymes can be useful in identifying enzyme activities in cells producing the virus and also in studying the biochemical mechanism of action of some of the antiviral agents.

Antiherpes drugs: promises and pitfalls

In recent years several selective antiherpes drugs have been developed which all show great promise for the systemic and topical treatment of herpes simplex virus and varicella-zoster virus infections. These new antiherpes agents include acyclovir, bromovinyldeoxyuridine, fluoroiodoaracytosine and phosphonoformate. Acyclovir has already been licensed for both topical and systemic use, and it is expected that other compounds will follow soon. Although this new generation of antiherpes drugs suffer from some drawbacks, i.e. narrow spectrum of activity, inefficacy during virus latency, and the possible emergence of drug-resistant virus strains, these limitations by no means outweigh the potentials of these drugs in the therapy and prophylaxis of herpesvirus infections in humans.